Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4283-4291

  Panchal, Rekha G ^a   Ulrich, Ricky L ^a   Lane, Douglas ^b   Butler, Michelle M ^c   Houseweart, Chad ^c   Opperman, Timothy ^c   Williams, John D ^c   Peet, Norton P ^c   Moir, Donald T ^c   Nguyen, Tam ^b   Gussio, Rick ^d   Bowlin, Terry ^c   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c MICROBIOTIX INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; DAPTOMYCIN; IMIDAZOLINE DERIVATIVE; MBX 1066; MBX 1090; MBX 1113; MBX 1128; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS ANTHRACIS; BACILLUS LICHENIFORMIS; BACILLUS MEGATERIUM; BACILLUS PUMILUS; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BREVIBACILLUS BREVIS; BURKHOLDERIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PLAGUE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; YERSINIA PESTIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; CELL DEATH; CELL LINE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MACROPHAGES; MICE; STAPHYLOCOCCUS AUREUS; YERSINIA PESTIS;

EID: 70349328445     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01709-08     Document Type: Article

References (25)

1. Alanis, A. J. 2005. Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med. Res. 36:697-705.
2. Anné, J., E. De Clercq, H. Eyssen, and O. Dann. 1980. Antifungal and antibacterial activities of diarylamidine derivatives. Antimicrob. Agents Chemother. 18:231-239.
3. Athamna, A., M. Massalha, M. Athamna, A. Nura, B. Medlej, I. Ofek, D. Bast, and E. Rubinstein. 2004. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J. Antimicrob. Chemother. 53:247-251.
4. Baillie, L. W. 2006. Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol. 101:594-606.
5. Balzarini, J., E. de Clercq, and O. Dann. 1983. Inhibitory activity of diarylamidine derivatives on murine leukemia L1210 cell growth. Investig. New Drugs 1:103-115. (Pubitemid 14095097)
6. Barrett, C. T., and J. F. Barrett. 2003. Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr. Opin. Biotechnol. 14:621-626.
7. Brosh, R. M., Jr., J. K. Karow, E. J. White, N. D. Shaw, I. D. Hickson, and V. A. Bohr. 2000. Potent inhibition of werner and bloom helicases by DNA minor groove binding drugs. Nucleic Acids Res. 28:2420-2430.
8. Bürli, R. W., J. A. Kaizerman, J. X. Duan, P. Jones, K. W. Johnson, M. Iwamoto, K. Truong, W. Hu, T. Stanton, A. Chen, S. Touami, M. Gross, V. Jiang, Y. Ge, and H. E. Moser. 2004. DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids. Bioorg. Med. Chem. Lett. 14:2067-2072.
9. Butler, M. M., W. A. Lamarr, K. A. Foster, M. H. Barnes, D. J. Skow, P. T. Lyden, L. M. Kustigian, C. Zhi, N. C. Brown, G. E. Wright, and T. L. Bowlin. 2007. Antibacterial activity and mechanism of action of a novel anilinouracilfluoroquinolone hybrid compound. Antimicrob. Agents Chemother. 51:119-127.
10. Chastre, J. 2008. Evolving problems with resistant pathogens. Clin. Microbiol. Infect. 14(Suppl. 3):3-14.
11. David, M. Z., D. Glikman, S. E. Crawford, J. Peng, K. J. King, M. A. Hostetler, S. Boyle-Vavra, and R. S. Daum. 2008. What is community-associated methicillin-resistant Staphylococcus aureus? J. Infect. Dis. 197:1235-1243.
12. Diep, B. A., G. G. Stone, L. Basuino, C. J. Graber, A. Miller, S. A. Etages, A. Jones, A. M. Palazzolo-Ballance, F. Perdreau-Remington, G. F. Sensabaugh, F. R. Deleo, and H. F. Chambers. 2008. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 197:1523-1530.
13. Doǧanay, M., and N. Aydin. 1991. Antimicrobial susceptibility of Bacillus anthracis. Scand. J. Infect. Dis. 23:333-335.
14. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126.
15. Hu, W., R. W. Burli, J. A. Kaizerman, K. W. Johnson, M. I. Gross, M. Iwamoto, P. Jones, D. Lofland, S. Difuntorum, H. Chen, B. Bozdogan, P. C. Appelbaum, and H. E. Moser. 2004. DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureus. J. Med. Chem. 47:4352-4355.
16. Hughes, J. M., and J. L. Gerberding. 2002. Anthrax bioterrorism: lessons learned and future directions. Emerg. Infect. Dis. 8:1013-1014.
17. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
18. Marshall, N. J., C. J. Goodwin, and S. J. Holt. 1995. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. Growth Regul. 5:69-84.
19. Monroe, S., and R. Polk. 2000. Antimicrobial use and bacterial resistance. Curr. Opin. Microbiol. 3:496-501.
20. National Committee for Clinical and Laboratory Standards (NCCLS). 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
21. Pathania, R., and E. D. Brown. 2008. Small and lethal: searching for new antibacterial compounds with novel modes of action. Biochem. Cell Biol. 86:111-115.
22. Rodríguez de Castro, F., O. R. Naranjo, J. A. Marco, and J. S. Violan. 2009. New antimicrobial molecules and new antibiotic strategies. Semin. Respir. Crit. Care Med. 30:161-171.
23. Tidwell, R. R., J. D. Geratz, O. Dann, G. Volz, D. Zeh, and H. Loewe. 1978. Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases. J. Med. Chem. 21:613-623.
24. Woese, C. R., J. C. Vary, and H. O. Halvorson. 1968. A kinetic model for bacterial spore germination. Proc. Natl. Acad. Sci. USA 59:869-875.
25. Wu, M., and R. E. Hancock. 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J. Biol. Chem. 274:29-35.